Difference between revisions of "NET of unknown primary"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Just 9 days left" to "Just 8 days left") |
Warner-admin (talk | contribs) m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==") |
||
(17 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> | |
− | |||
− | < | ||
− | |||
− | |||
− | |||
− | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | + | <!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].--> |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
+ | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
==[http://www.esmo.org/ ESMO]== | ==[http://www.esmo.org/ ESMO]== | ||
− | *[http://annonc.oxfordjournals.org/content/26/suppl_5/v133.full.pdf+html Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | + | *'''2015:''' [http://annonc.oxfordjournals.org/content/26/suppl_5/v133.full.pdf+html Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/26314775/ PubMed] |
− | == | + | ==NCCN== |
− | *[https://www.nccn.org/ | + | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1451 NCCN Guidelines - Occult Primary (Cancer of Unknown Primary (CUP)] |
=All lines of therapy= | =All lines of therapy= | ||
Line 27: | Line 23: | ||
[[Category:NET of unknown primary regimens]] | [[Category:NET of unknown primary regimens]] | ||
+ | [[Category:Site-agnostic regimens]] | ||
+ | [[Category:Malignant solid neoplasm]] |
Revision as of 11:35, 13 May 2024
0 regimens on this page
0 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
- 2015: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
All lines of therapy
- Poorly differentiated or small cell tumors can be treated with small cell lung cancer regimens.
- Moderate to well-differentiated neuroendocrine tumors can be treated with regimens for neuroendocrine tumors.